| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers G > Headlines for Gilead Sciences Inc. > News item |
Gilead Sciences licenses specialty cancer product DaunoXome to Diatos
By E. Janene Geiss
Philadelphia, May 11 - Diatos SA said Thursday that it has signed an exclusive licensing agreement with Gilead Sciences, Inc. on the worldwide development and commercialization rights to DaunoXome.
DaunoXome is a marketed liposomal formulation of daunorubicin, which has been approved for AIDS/HIV-related Kaposi's sarcoma and is sold by Gilead in more than 20 countries, according to a company news release.
DaunoXome also has been evaluated in clinical studies for potential efficacy and safety in acute myeloid leukemia. Daunorubicin is a widely used chemotherapeutic agent used principally in hematological malignancies, officials said.
Under terms of the agreement, Diatos said it was granted exclusive worldwide development and commercialization rights to DaunoXome in Kaposi's sarcoma and all other potential indications.
In exchange, Gilead said it will receive upfront and milestone payments of up to $4.7 million, based on regulatory approval of new indications, and royalties on net sales.
On the basis of data derived from DaunoXome's commercial use and from various clinical studies in acute leukemic diseases, Diatos said it intends to seek approval from European regulatory authorities for the use of DaunoXome in acute leukemia.
Acute myeloid leukaemia is a common form of blood cancer affecting more than 12,000 new patients per year in Europe. Diatos said it intends to continue to market DaunoXome in Kaposi's sarcoma in Europe and Brazil.
Diatos is a Paris-based privately held biopharmaceutical company.
Gilead Sciences is a Foster City, Calif., biopharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.